Teva Amends Senior Notes Indenture
Teva Pharmaceutical issued a Sixth Supplemental Indenture creating new Series 4.250% and 4.625% Senior Notes, to market impact.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed